Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females
One hundred and ninety eight females aged 12-15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine, Cervarix® (group 1), which was routinely offered in t...
Saved in:
Main Authors: | Tao Haskins-Coulter (Author), Jo Southern (Author), Nick Andrews (Author), Elizabeth Miller (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2017-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
by: Maria Zurek Munk-Madsen, et al.
Published: (2018) -
Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9
by: Nitesh K. Kunda, et al.
Published: (2019) -
GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007) -
GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007) -
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)
by: Vandana A Govan
Published: (2008)